Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

[1]  M. Labopin,et al.  Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial , 2015, Cancer.

[2]  E. Carreras.  How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation , 2015, British journal of haematology.

[3]  B. Gruhn,et al.  Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation , 2015, Journal of Cancer Research and Clinical Oncology.

[4]  M. Labopin,et al.  Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure , 2014 .

[5]  P. Chevallier,et al.  Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  P. Chevallier,et al.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT , 2014, Bone Marrow Transplantation.

[7]  P. Veys,et al.  BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation , 2013, British journal of haematology.

[8]  M. Díaz-Ricart,et al.  Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  M. Labopin,et al.  Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. DeFor,et al.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. , 2013, Blood.

[11]  P. Richardson,et al.  Drug safety evaluation of defibrotide , 2013, Expert opinion on drug safety.

[12]  A. Schulz,et al.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.

[13]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[14]  M. Díaz-Beyá,et al.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  A. Gratwohl,et al.  Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[16]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[17]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Díaz-Ricart,et al.  Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Allen R. Chen,et al.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  R. D'Agostino,et al.  Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control. , 2009 .

[21]  F. Ichinose,et al.  The Role of Endothelium , 2009 .

[22]  M. Díaz-Ricart,et al.  The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  P. Richardson,et al.  Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. , 2008, Blood.

[24]  B. Biedermann.  Vascular endothelium and graft-versus-host disease. , 2008, Best practice & research. Clinical haematology.

[25]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  H. Lazarus,et al.  Iron overload in hematopoietic cell transplantation , 2008, Bone Marrow Transplantation.

[27]  Y. Lau,et al.  Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.

[28]  D. Allan,et al.  Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  A. Schulz,et al.  Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide , 2006, Bone Marrow Transplantation.

[30]  I. Tleyjeh,et al.  Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis , 2006, Bone Marrow Transplantation.

[31]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  B. George,et al.  Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. , 2004, Blood.

[33]  P. Thall,et al.  Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. , 2004, Blood.

[34]  O. Kocaman,et al.  Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. , 2004, Transplantation proceedings.

[35]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[36]  C. Solano,et al.  Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. , 2003, Experimental hematology.

[37]  Allen R. Chen,et al.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.

[38]  M. Remberger,et al.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.

[39]  S. Uemoto,et al.  A Successful Liver Transplantation for Refractory Hepatic Veno‐Occlusive Disease Originating from Cord Blood Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  Ha Yeon Lee,et al.  A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[41]  G. McDonald,et al.  Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.

[42]  E. Carreras.  Veno‐occlusive disease of the liver after hemopoietic cell transplantation , 2000, European journal of haematology.

[43]  K. Ohashi,et al.  The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno‐occlusive disease after stem cell transplantation , 2000, American journal of hematology.

[44]  H. Bismuth,et al.  Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation , 2000, Bone Marrow Transplantation.

[45]  Je-Hwan Lee,et al.  Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study , 1998, Bone Marrow Transplantation.

[46]  D. Neuberg,et al.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.

[47]  N. Callander,et al.  Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation , 1998, Annals of Internal Medicine.

[48]  E. Holler,et al.  Influence of bacterial endotoxin on the allogenicity of human endothelial cells , 1998, Bone Marrow Transplantation.

[49]  L. DeLeve.  Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation , 1996, Hepatology.

[50]  A. Nagler,et al.  Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. , 1996, Transplantation.

[51]  G. Anderson,et al.  Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[53]  A. Grañena,et al.  On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease , 1993, Annals of Hematology.

[54]  P. Brousset,et al.  Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. , 1992, Blood.

[55]  J. Ritz,et al.  HEPATIC DYSFUNCTION FOLLOWING T‐CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION , 1991, Transplantation.

[56]  M. Labopin,et al.  Prophylactic heparin does not prevent liver veno‐occlusive disease following autologous bone marrow transplantation , 1991, European journal of haematology.

[57]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[58]  N. Kröger,et al.  Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome , 2014, Bone Marrow Transplantation.

[59]  P. Richardson,et al.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[60]  H. Halkin,et al.  Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[61]  K. Cooke,et al.  The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[62]  W. Aird.  The Role of the Endothelium , 2007 .

[63]  M. Pillon,et al.  A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. , 2005, Haematologica.

[64]  R. Storb,et al.  Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. , 2004, Blood.

[65]  M. Díaz-Ricart,et al.  Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK. , 2004, Haematologica.

[66]  A. Gratwohl,et al.  Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. , 1998, Blood.

[67]  P. Ljungman,et al.  Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. , 1998, Blood.

[68]  G. McDonald,et al.  Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. , 1992, Blood.

[69]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.